Condition: Breast Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.
This description comes directly from the study's public registry record.
ZHENGJUN YANG, MD · 8613512891631 · yangxinpiaoxue001@163.com
QINGSONG PANG, MD · 8618622221203 · pangqingsong@tjmuch.com
Always discuss trial participation with your own doctor first.
| Tianjin medical university cancer institute and hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06498154